Aarushi XXX serves as a Research Fellow in the Department of Economics at the University of Bologna, Italy. Her institutional affiliation is formally maintained through the university's central academic structure in Bologna. Her educational background includes: Ph.D. in Economics from the University of Queensland (awarded February 2025) Master in Applied Econometrics from the University of Queensland BSc in Economics & Management from the University of St Andrews (with year abroad at Purdue University) Research focuses intensely on applied microeconomics within health economics, specifically examining economic burdens of non-communicable diseases. Her work quantifies impacts across conditions including infertility, obesity, colorectal cancer, chronic kidney disease, congestive heart failure, and breast cancer. This specialized niche combines econometric modeling with public health policy analysis, demonstrating methodological rigor in assessing disease-related productivity losses and healthcare system strain.
Alexis Battle is an Associate Professor at Johns Hopkins University with appointments in Biomedical Engineering , Computer Science , and Genetic Medicine (secondary). She directs the Malone Center for Engineering in Healthcare and serves as Deputy Director of the Data Science and AI Institute . Educated at Stanford University (PhD in Computer Science, 2013), Battle transitioned to academia after leadership roles at Google. Research Focus: Battle’s work bridges genomics and machine learning , emphasizing the impact of genetic variation on human health. Her lab develops tools like Watershed to predict functional effects of rare variants, aiming to enhance rare disease diagnosis. Key themes include non-coding DNA analysis , personalized genomics , and systems biology , with applications in cardiovascular disease and neurodegenerative disorders . Publications & Awards: Over 60 peer-reviewed articles in journals like Nature , Science , and Genome Biology , with recent emphasis on single-cell transcriptomics , multiomics integration , and telomere biology . Recipient of the President’s Frontier Award (2022), Microsoft Investigator Fellowship (2019), and Searle Scholar (2016). Scientific Awards: 2022 President’s Frontier Award 2019 Microsoft Investigator Fellowship 2019 Johns Hopkins Discovery Award 2017 Johns Hopkins Catalyst Award 2016 Searle Scholar Advising & Funding: Mentors 11 PhD students, 3 undergraduates, and postdoctoral fellows. Her research is funded by NIH, Searle Scholars, and institutional grants. The Battle Lab collaborates on projects like the GTEx Consortium , focusing on gene regulation and clinical genomics .
Jonathan W. Friedberg, M.D., M.M.Sc. is the Director of the Wilmot Cancer Institute and Professor in the Department of Medicine, Hematology/Oncology at the University of Rochester School of Medicine and Dentistry. He holds the Samuel E. Durand Chair in Medicine and leads one of the nation's premier lymphoma programs. Dr. Friedberg is internationally recognized for his expertise in lymphoma treatment, particularly in developing novel therapies and clinical trial approaches. Dr. Friedberg's research focuses on lymphoma, with particular expertise in Hodgkin lymphoma, non-Hodgkin lymphoma, Waldenstrom macroglobulinemia, and chronic lymphocytic leukemia. His work spans the entire treatment continuum from diagnosis through novel therapies including autologous stem cell transplantation and CAR-T cell interventions. He has built a comprehensive lymphoma program with expertise spanning hematopathology, radiation oncology, dermatology, and neurology, in addition to hematology and medical oncology. His research interests include developing risk-adapted treatment strategies, investigating novel therapeutic agents, and improving outcomes for patients with various lymphoma subtypes. Dr. Friedberg's extensive publication record demonstrates his leadership in lymphoma research, with recent work focusing on immunotherapy combinations, predictive modeling, risk stratification, and novel treatment approaches for various lymphoma subtypes. His research has significantly contributed to the understanding and treatment of lymphomas, particularly in developing more personalized and effective treatment strategies. Scientific Awards: Faculty Academic Mentoring Award (2012) Scholar in Clinical Research (2008) America's Top Doctors Selection (2008) Jacob Gitelman Award (2007) Lawrence A. Kohn Senior Teaching Fellow (2004-2006) Clinical Investigator Career Development Award (2003) Clinical Oncology Research Fellowship "Immunotherapy of Hodgkin's Disease" (2001-2003) Rising stars program for innovative research (2001-2003) As Director of the Wilmot Cancer Institute, Dr. Friedberg leads numerous clinical trials and research initiatives focused on advancing lymphoma treatment. He is actively involved in SWOG and has served in leadership roles for multiple clinical trials investigating novel therapies for lymphoma patients. His practice team includes Anna Morrison, R.N., and Kerri Hugelmaier, N.P., providing comprehensive care for lymphoma patients. Dr. Friedberg has established the Lymphoma Epidemiology of Outcomes (LEO) Consortium, a large observational cohort study supporting broad research on NHL prognosis and survivorship. His leadership extends to national organizations where he contributes to developing clinical practice guidelines and consensus recommendations for lymphoma treatment.
Dr. Samira Lakhal-Littleton is an Associate Professor of Cell Physiology and MRC Senior Non-Clinical Research Fellow at the University of Oxford, affiliated with the Department of Physiology, Anatomy and Genetics and Brasenose College. Her research focuses on iron homeostasis, systems biology, and oxygen sensing mechanisms in cardiovascular and systemic physiology. Education: BSc in Human Genetics (University College London), DPhil in Molecular Medicine (University of Oxford) Her work bridges cell physiology and translational medicine, with key discoveries on hypoxia-inducible factors (HIFs), iron regulatory genes TMPRSS6 and GDF15 , and the role of hepcidin in altitude adaptation and chronic diseases. She utilizes tissue-specific animal models to study iron regulation in heart, kidney, placenta, and vasculature. Recent publications highlight her contributions to understanding: FLASH radiotherapy effects linked to iron-dependent lipid peroxidation Clinical implications of myocardial iron dynamics in heart failure Hepcidin's role in vascular protection and placental iron transfer Biomarker development for predictive iron deficiency diagnostics Scientific Leadership: British Heart Foundation Intermediate Fellowship (2012) MRC Senior Fellowship (2020) BioIron Society Board Member (2019) She collaborates with clinical teams on translational projects and serves as a Tutorial Fellow in Medicine at Brasenose College, mentoring students in physiological sciences.
Dr. Pascal Syren is a **Researcher** and **Resident** at Heidelberg University Hospital (UKHD), affiliated with the **Department of Cardiology, Angiology, and Pulmonology** and the **Heidelberg Center for Cardiac Arrhythmias**. His academic role includes contributing to the **Group of Molecular and Translational Cardiac Electrophysiology**, focusing on epigenetic and molecular mechanisms underlying cardiac arrhythmias and heart failure. He holds a PhD from Heidelberg University (2021) on histone deacetylases' influence in cardiac electrophysiology. **Research Interests**: Cardiac electrophysiology, epigenetic regulation (HDACs), ventricular and atrial arrhythmias, echocardiography, and translational cardiology. His work spans basic science to clinical applications, emphasizing ion channel remodeling and therapeutic targets for heart rhythm disorders. **Awards**: Recipient of the **Ernst & Berta Grimmke Foundation Research Grant (2023–2024)** and **Otto-Hess Scholarship (2017–2018)** from the German Cardiac Society. His research bridges molecular mechanisms with clinical cardiology, with contributions to understanding HDAC2's role in action potential dynamics. **Publications**: Over 8 peer-reviewed articles (2016–2025) in journals like *Basic Research in Cardiology* and *Cells*, focusing on histone deacetylase pathways, atrial fibrillation, and ventricular arrhythmia models. Recent work explores neonatal cardiomyocyte electrophysiology and TREK-1 potassium channels in heart failure. **Affiliations**: Active member of the **German Cardiac Society (DGK)** and **European Society of Cardiology (ESC)**, contributing to interdisciplinary cardiac arrhythmia research at Heidelberg's medical faculty.
Michael Yeager, PhD, serves as an Associate Clinical Professor in the School of Medicine at the University of Colorado Denver, focusing on cardiopulmonary pathophysiology with emphasis on pulmonary hypertension and heart failure mechanisms. He completed his PhD at the University of Colorado Health Sciences Center in 2002, establishing foundational expertise in vascular biology. His research program investigates immunological and molecular drivers of pulmonary vascular disease, particularly the roles of autoantibodies, fibrocytes, and inflammatory cascades in disease progression. Analysis of his 14 publications (2012-2015) reveals consistent exploration of biomarker discovery, vascular remodeling, and immune dysregulation across pediatric and adult pulmonary hypertension. Key methodological approaches include proteomics, animal modeling, and molecular interrogation of cellular stress responses, with significant translational implications for personalized therapeutic strategies. Professional recognitions include: Outstanding Faculty award from Tau Beta Pi (2019) Chancellor's Teaching Recognition Award from the University of Colorado (2016) Dr. Yeager maintains active clinical research collaborations at Children's Hospital Colorado while mentoring within the medical school curriculum. His work bridges basic science discovery with clinical application through ongoing investigations into endothelial dysfunction and inflammatory mediators. Affiliated with the Department of Medicine, he contributes to pulmonary vascular research initiatives and participates in professional societies including the American Thoracic Society, American Heart Association, and T21 Research Society.
Ruofan Yao serves as an Associate Professor in the Department of Gynecology and Obstetrics at Loma Linda University School of Medicine. Holding dual qualifications as an MD and MPH, Dr. Yao maintains an active research profile with 40 publications spanning 2013-2025, reflecting sustained scholarly productivity in maternal-fetal health. Dr. Yao's educational background combines clinical medicine (MD) with population health expertise (MPH), enabling interdisciplinary research at the intersection of obstetrics and environmental health. This foundation supports investigations into critical windows of vulnerability during pregnancy and population-level risk factors. Research focuses on environmental exposures (particularly wildfire proximity) and maternal health conditions (notably obesity) as determinants of birth outcomes. Key areas include congenital heart defects, neural tube defects, perinatal mortality, and cardiovascular complications in pregnancy. Methodologically, the work employs epidemiological approaches to analyze large datasets and identify modifiable risk factors. Analysis of 15 most recent publications (2023-2025) reveals a clear trajectory toward environmental obstetrics, with 60% examining wildfire impacts on congenital anomalies and 40% investigating obesity-related pregnancy complications. The research demonstrates increasing methodological sophistication in spatial epidemiology and temporal vulnerability assessment, primarily focused on U.S. populations. No scientific awards are documented in the available materials. Mentoring activities and grant funding details are not specified in the provided information. The research appears integrated within broader institutional maternal-fetal medicine initiatives at Loma Linda University, though specific lab structures or team compositions are not described.
Professor Nicholas Buckley is a leading academic in Clinical Pharmacology at the University of Sydney and holds a Visiting Professor position at the University of Peradeniya, Sri Lanka. He serves as Research Director for the South Asian Clinical Toxicology Research Collaboration (SACTRC) and is a Consultant Clinical Pharmacologist & Toxicologist at the NSW Poisons Information Centre and Royal Prince Alfred Hospital. His work focuses on improving clinical toxicology practices, poison control policies, and understanding mechanisms of drug toxicity. Co-founder of SACTRC for agrochemical poisoning and snakebite research Chair of Australian Therapeutic Guidelines - Toxicology writing group Editorial roles in Clinical Toxicology, Drug Safety, and Australian Prescriber Research Interests include toxicovigilance, epidemiology of poisoning, acute kidney injury in poisoning/snakebite, pesticide safety interventions, antidote development, and pharmacoepidemiology of psychotropic drugs. His work combines clinical trials, population surveillance, and translational research. Scientific Contributions span 440+ peer-reviewed articles and 22 book chapters, with continuous funding since 2002. He has supervised over 20 higher degree students and leads international collaborations in low-and-middle-income countries through NIHR RIGHT4. Key Affiliations : Member of Charles Perkins Centre, Australian Medicines Handbook Editorial Advisory Board, and NIHR RIGHT4 programme.
Tianxi Cai, ScD, holds the John Rock Professorship in Population and Translational Data Sciences at the Harvard T.H. Chan School of Public Health and is a Professor of Biomedical Informatics at Harvard Medical School. She directs the Translational Data Science Center for a Learning Health System (CELEHS). Her work bridges clinical and basic science data to advance personalized medicine and disease understanding. Institution: Harvard University Departments: Biostatistics (T.H. Chan School) and Biomedical Informatics (HMS) Key Roles: Faculty member since 2002, NIH-funded researcher, and leader in EHR data analytics Research focuses on biomarker evaluation, predictive modeling, high-dimensional data analysis, and survival analysis. Collaborates with the I2B2 Center to integrate clinical and genomic data. Active in developing semi-supervised learning methods for noisy EHR data and real-world evidence generation. Funding : Recent grants include NIH projects on rheumatoid arthritis treatment response (R01AR080193, R21AR078339) and semi-supervised EHR denoising (R01LM013614). Co-leads initiatives on chronic disease endpoints using multi-source data (U01FD007929). Labs/Teams : Directs CELEHS and leads the Cai Lab, focusing on translational data science and machine learning applications in healthcare.
Björn Pasternak is a Research Professor leading the Pharmacoepidemiology group at the Department of Medicine, Solna, Karolinska Institutet. His team specializes in large-scale registry studies focused on adverse drug effects, with research programs in pediatric pharmacoepidemiology, safety of diabetes medications, and rapid assessment of drug safety concerns. The group leverages high-quality epidemiological methods to inform evidence-based clinical decisions. Pasternak's research interests span pharmacoepidemiology, drug safety, diabetes outcomes, cardiovascular risk, and perinatal health. His work utilizes nationwide registries to evaluate real-world drug effects, socioeconomic disparities in treatment, and long-term outcomes of chronic therapies. Key focuses include GLP-1 receptor agonists, SGLT2 inhibitors, antibiotic use in pregnancy, and opioid safety. Recent publications demonstrate strong emphasis on Scandinavian cohort studies of diabetes medications (GLP-1 agonists, SGLT2 inhibitors) and their associations with thyroid cancer, liver events, intestinal obstruction, and cardiovascular/renal outcomes. Other trends include perinatal pharmacovigilance (antibiotics, acid-suppressive drugs) and neurodegenerative risks in athletes.
Professor Carlo Pappone is a Full Professor of Cardiology at Vita-Salute San Raffaele University (since 2019) and Director of the Arrhythmology Department at IRCCS Policlinico San Donato Hospital (since 2015). He has held previous academic/clinical leadership roles at IRCCS San Raffaele Hospital (2000-2010), Villa Maria Cecilia Hospital (2010-2015), and University of Naples Federico II (1990-2000). With 212 publications in top journals like NEJM, JAMA, and Circulation, he has made significant contributions to cardiac arrhythmia research. Current Positions Vita-Salute San Raffaele University (2019-present): Full Professor of Cardiology IRCCS Policlinico San Donato Hospital (2015-present): Director of Arrhythmology Department Previous Roles University of Naples Federico II (1990-2000) University of Michigan Ann Harbor (1990-2000) IRCCS San Raffaele Hospital (2000-2010) Villa Maria Cecilia Hospital (2010-2015) Research Focus: Specializing in cardiovascular diseases, his work spans atrial fibrillation ablation techniques, Brugada syndrome pathogenesis, heart failure device therapy, and ion channel disorders. His H-index of 53 and 18,407 citations reflect his substantial academic impact. Notable Scientific Contributions Author of 44 patents Principal Investigator in 14 clinical trials (clinicaltrials.gov) Developed circumferential pulmonary vein ablation technique Innovator in biventricular pacing systems for heart failure Pioneered research on non-excitatory current for cardiac contractility Scientific Recognition Awarded as Elite Reviewer of JACC (2005) Editorial Board Member of 6 leading journals Reviewer for NEJM, JAMA, Lancet, and Nature Medicine Education Medical Doctorate: University of Naples Federico II
Professor Robert McLaughlin is a faculty member in the School of Biomedicine at the University of Adelaide, affiliated with the Faculty of Health and Medical Sciences. He leads the Bioengineering Imaging Group and serves as Managing Director of the start-up Miniprobes. His research focuses on developing optical imaging technologies, including non-invasive tools for blood flow assessment and miniaturized imaging probes. He has secured over $14M in research grants and holds an h-index of 45 with 98 journal papers, 7 patents, and 2 book chapters. Prof. McLaughlin’s career includes roles at the University of Oxford and Siemens Medical Solutions, followed by academic leadership since 2007. His innovations span optical coherence tomography (OCT), fluorescence imaging, and dual-modality systems for clinical applications. Awards include the 2014 WA Innovator of the Year, 2015 Australian Innovation Challenge, and 2016 South Australian Premier’s Research Fellowship. His research emphasizes practical medical solutions, such as imaging needles for deep-tissue diagnostics and optical devices for real-time surgical monitoring. The Bioengineering Imaging Group collaborates with industry and academia to translate technologies into clinical practice.
Jim Hall is a Professor of Climate and Environmental Risk at the University of Oxford's School of Geography and the Environment, and serves as Director of Research there. He is also a Visiting Fellow at Linacre College and holds leadership roles including Chair of the Science Advisory Committee at IIASA, and Expert Advisor to the UK's National Infrastructure Commission. His work focuses on systemic risk analysis, infrastructure resilience, and policy implications of climate change adaptation. Prof Hall has pioneered methodologies like the National Infrastructure Systems Model (NISMOD) and chairs the Data and Analytics Facility for National Infrastructure (DAFNI). His research spans flood risk management, energy systems decarbonization, and transboundary water resource conflicts in regions such as the Eastern Nile Basin and the Caribbean. Key research areas include robust decision making under uncertainty, info-gap theory applications, and integrated assessments of human-environmental systems. He has contributed to major international assessments, including the IPCC's Fourth Assessment Report, and developed frameworks for multi-hazard stress testing of infrastructure networks. Scientific Awards: George Stephenson Medal (2001), Prince Sultan Prize for Water (2018), Royal Academy of Engineering Fellowship (2010) His advising and grants work includes mentoring a DPhil student Erin Canning and leading projects like MARIUS and ENHANCE. He has also developed innovative modeling tools for coastal erosion prediction and probabilistic assessments of global shipping fuel transitions. Prof Hall’s research groups actively engage in interdisciplinary projects, including the Oxford Martin Programme on Resource Stewardship and the UK Infrastructure Transitions Research Consortium. His work emphasizes bridging scientific analysis with actionable policy solutions for climate adaptation.
Vishal Ahuja is an Associate Professor and Corrigan Research Professor at Southern Methodist University's Cox School of Business, with adjunct faculty status at University of Texas Southwestern Medical Center. He focuses on decision analytic tools for healthcare improvement through operations management. PhD, University of Chicago Booth School of Business MBA, University of Chicago Booth School of Business His research interests span healthcare operations, service optimization, and AI applications in clinical decision-making. He collaborates with the Department of Veterans Affairs, Parkland Hospital, and pediatric institutions to address care quality and delivery efficiency. Recent publications emphasize predictive modeling for chronic disease management, adaptive clinical trial design, and regulatory healthcare policy. Awards include the Dlin/Fischer Clinical Research Award (2021), INFORMS Pierskalla Award (2012), and 2025 AI75 recognition for Dallas-Fort Worth AI leadership. D CEO Excellence in Healthcare Award - Outstanding Healthcare Innovator (2023) NSF Game Changer Academies for Advancing Research Innovation (2022) C. Jackson Grayson Faculty Innovation Award (2022-23) At SMU, he teaches graduate courses in operations, supply chain, and service management, integrating corporate sector experience from chemical and consumer goods industries. His work has been cited by the FDA in safety labeling changes workshops.
University of California , Santa Barbara (UCSB)United States
Angela Pitenis is an Associate Professor in the Department of Materials at the University of California, Santa Barbara (UCSB), within the College of Engineering. Her research focuses on interfacial phenomena in soft materials, particularly friction, adhesion, wear, and deformation of complex surfaces ranging from living cells to polymer nanocomposites. She employs advanced experimental techniques such as microscopy, spectroscopy, and interferometry to study these interfaces under extreme conditions and within buried environments. Her work has direct applications in healthcare, energy sustainability, and engineering design. Prof. Pitenis holds a Ph.D., M.Sc., and B.S. in Mechanical Engineering from the University of Florida. Her research group investigates biomaterials, hydrogel lubrication, and bioinspired materials, with recent studies addressing implant-associated inflammation, tumor cell dynamics in 3D microgels, and pH-responsive hydrogel friction. She is affiliated with the Materials Research Lab at UCSB and contributes to interdisciplinary projects at the intersection of materials science and biology. Notable research trends in her work include the development of biocompatible lubricious surfaces, understanding friction-induced biological responses, and designing smart materials with tunable mechanical properties. Her studies on photoresponsive hydrogels and superlubricious materials highlight innovations in responsive and adaptive material systems. Pitenis emphasizes in situ experimental methods and has pioneered techniques for analyzing dynamically evolving material interfaces. Her research also extends to marine biomaterials, such as the mechanical resilience of sessile tunicates, and explores applications in medical implants, bioreactors, and energy systems. While specific awards are not listed here, her contributions reflect a commitment to advancing soft matter tribology and biomaterials science.
